Progesterone Receptor Negative Recruiting Phase 1 Trials for Docetaxel (DB01248)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03218826PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryTreatment